Lupus & antiphospholipid syndrome
Litifilimab reduces skin and joint disease in participants with SLE: additional results from Part A of the phase II LILAC study
Authors' conclusion
These findings characterise litifilimab’s effects on skin and joints and complement the LILAC Part A primary efficacy results, supporting the benefit of litifilimab for skin and joint manifestations in SLE.
Study context
- Population
- Adults with SLE from LILAC Part A with active skin and/or joint disease at baselinemodified intent-to-treat population subsets with active skin and/or joint disease at baseline
- Participants
- 64 vs 56
- Comparison
- Litifilimab versus placebo
- LITIFILIMAB 450 MGn = 64
- PLACEBOn = 56
Methodological detailsphase II, modified intent-to-treat population subsets, placebo-controlled
- Phase II
- Modified intent-to-treat population subsets
- Placebo-controlled
Primary result
As reported in the abstract
- Greater proportions of participants achieved CLASI-50 and CLASI-70 responses with litifilimab than placebo
Further findings
Joint-50 response, total tender plus total swollen joints · week 24
Joint-50 response, total tender and/or swollen joints · week 24
Joint-50 response, total tender and swollen joints · week 24
Resolution of SLEDAI-2K rash · week 24
Resolution of SLEDAI-2K arthritis · week 24
Resolution of SLEDAI-2K rash and arthritis · week 24
Improvement of ≥1 grade in the BILAG-2004 mucocutaneous and musculoskeletal domains · week 24
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →